BioFactura

BioFactura, Inc. is a biopharmaceutical company specializing in the development and manufacturing of high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs. The company operates in the global biomedical and national biodefense markets, addressing unmet needs through its proprietary StableFastTM Biomanufacturing Platform. This platform enables rapid and stable production of biosimilars and other biologics, enhancing efficiency and reducing costs. BioFactura's business model involves partnering with healthcare networks, legal firms, and other stakeholders to secure investments and contracts, such as the recent $67.4 million advanced development contract for a smallpox biodefense therapeutic. The company generates revenue through the development and sale of its biopharmaceutical products and services, catering to clients in the healthcare and biodefense sectors.

Keywords: biosimilars, biodefense, biomanufacturing, StableFast, monoclonal antibodies, biopharmaceutical, biomedical, novel drugs, therapeutic, healthcare.